Report LibraryAll Reports
Datamonitor Healthcare CNS Disease Analysis: Bipolar Disorder
August 20, 2021
The bipolar disorder (BD) market is highly genericized, consisting of antipsychotics, anticonvulsants, and mood stabilizers such as lithium. The atypical antipsychotic market is the most dominant of the drug classes indicated for BD, and the oral atypical antipsychotic market is highly competitive with many generic alternatives available. The atypical long-acting injectable (LAI) antipsychotic market currently sees little competition and is therefore one of the key areas to target for growth, along with the development of drugs focusing on other underserved BD patient segments.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Bipolar Disorder|